U.S. FDA Assessing Capability To Amplify Surveillance Of Indian, Chinese OTC Manufacturers - PharmAsia Summit
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - U.S. FDA is gathering information that will likely help the agency intensify its gaze on Indian and Chinese OTC, nutraceutical and traditional medicine manufacturers that use a registration loophole to export products to the U.S. under less stringent oversight
You may also be interested in...
U.S. FDA Long-Term Globalization Strategy Under Development
Coping with an increasingly global device and drug industry will require a paradigm shift that relies less on U.S. FDA's own staff and more on data and resource sharing with other countries, the agency says
U.S. FDA Long-Term Globalization Strategy Under Development
Coping with an increasingly global device and drug industry will require a paradigm shift that relies less on U.S. FDA's own staff and more on data and resource sharing with other countries, the agency says
U.S. FDA China Country Head Chris Hickey On FDA's Mission In China: An Interview With PharmAsia News (Part 2 of 2)
U.S.FDA established offices in China in 2008 to improve oversight of products exported to the U.S., and to establish stronger working relationships with China's State FDA. The mission of the office initially was to implement two export agreements signed with China in December 2007 to enhance regulatory cooperation in the areas of food, drugs, medical devices and animal feed. PharmAsia News' China and Australia bureaus spoke to FDA China Country Director Christopher Hickey about the mission of the China office and progress being made in China. This is part two of a two-part interview; part one appeared in a recent issue of PharmAsia News.